[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir",
    "summary": "Broadcom's AI surge, J&J's resilient growth, and Palantir's defense-driven momentum headline today's top analyst reports.",
    "url": "https://finnhub.io/api/news?id=3d6c8b66b0640861d0715678cf516dc59ba0eaca55952baf49d5e80f42262d10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761858000,
      "headline": "Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir",
      "id": 137274898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Broadcom's AI surge, J&J's resilient growth, and Palantir's defense-driven momentum headline today's top analyst reports.",
      "url": "https://finnhub.io/api/news?id=3d6c8b66b0640861d0715678cf516dc59ba0eaca55952baf49d5e80f42262d10"
    }
  },
  {
    "ts": null,
    "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
    "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
    "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844560,
      "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
      "id": 137268736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
      "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=b98e313481237248ba475f9a12a41223dff0780d7fab110209859337fe084791",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831602,
      "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
      "id": 137268737,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=b98e313481237248ba475f9a12a41223dff0780d7fab110209859337fe084791"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
    "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
    "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761823920,
      "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
      "id": 137266539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
      "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
    "summary": "RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
    "url": "https://finnhub.io/api/news?id=35d1a550acc03b16b9fabeff7e6485c646a32923ef0a177b185a476b0e35f10f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761820200,
      "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
      "id": 137266540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
      "url": "https://finnhub.io/api/news?id=35d1a550acc03b16b9fabeff7e6485c646a32923ef0a177b185a476b0e35f10f"
    }
  },
  {
    "ts": null,
    "headline": "Is Ulta Beauty's (ULTA) CFO Appointment a Signal for Change Amid Margin and Demand Concerns?",
    "summary": "On October 10, 2025, Ulta Beauty's Board of Directors appointed Christopher DelOrefice as Chief Financial Officer, effective December 5, 2025, following an extensive leadership career at Becton Dickinson & Company and Johnson & Johnson. The appointment comes as Ulta Beauty prepares for its third-quarter results amidst analyst expectations for a double-digit earnings drop and heightened margin pressures this year. We'll explore how investor focus on Ulta Beauty's upcoming earnings amid margin...",
    "url": "https://finnhub.io/api/news?id=ae84e10d98338d19759da487cd73182e5d6827ea6374e4f075fd10b32a3f9e57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761815805,
      "headline": "Is Ulta Beauty's (ULTA) CFO Appointment a Signal for Change Amid Margin and Demand Concerns?",
      "id": 137266541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "On October 10, 2025, Ulta Beauty's Board of Directors appointed Christopher DelOrefice as Chief Financial Officer, effective December 5, 2025, following an extensive leadership career at Becton Dickinson & Company and Johnson & Johnson. The appointment comes as Ulta Beauty prepares for its third-quarter results amidst analyst expectations for a double-digit earnings drop and heightened margin pressures this year. We'll explore how investor focus on Ulta Beauty's upcoming earnings amid margin...",
      "url": "https://finnhub.io/api/news?id=ae84e10d98338d19759da487cd73182e5d6827ea6374e4f075fd10b32a3f9e57"
    }
  }
]